Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC

The Lancet 2026

View at publisher

Authors: Zofia Piotrowska

DOI: 10.1016/s0140-6736(25)02116-6

Cited by: 1

References: 9

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Liver physiology and pathology Fibroblast Growth Factor Research

References 9